tirzepatide

4 statements across 1 episodes · 3 bullish · 0 bearish · 1 people on the record · first statement Nov 11, 2025 by Dave Ricks · said 8 times in 1 episodes since 2025 · across every show →

Mentions by year

brought up most by Dave Ricks (5), Patrick Collison (3)

tap a year for its mentions
0041812025episodesmentions
0112025episodes it came up in
0040.5812025episodesmentions per episode
2025 8 mentions in 1 episode

every mention, scene by scene, with the transcript →

Everything said about tirzepatide, oldest first

Nov 11, 2025 positive
Assertion Supported
Ricks: Tirzepatide's US patent extends into the late 2030s
“I think Terseptide's U.S. Patent is late thirties or foregrip on the oral beyond that.”
Dave Ricks Nov 11, 2025 ▶ 1:49:39 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Nov 11, 2025
What-if
Ricks: Tirzepatide would be universally reimbursed if introduced in 1972
“If the first medicine we had to treat metabolic conditions was terzepatide in 1972, I have no doubt it would be reimbursed everywhere and broadly used in the system.”
Dave Ricks Nov 11, 2025 ▶ 26:56 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Nov 11, 2025 positive
Insight
Ricks: Expensive cardiovascular trial mandates protect GLP-1 incumbents from low-cost competition
“Now, by happy accident, we are all now really pleased with, like, incretins, like our trisepetide to run them because they frequently demonstrate massive benefit. Uncardiovascular. And in some ways, it creates a barrier to entry for the next low-cost Chinese p…”
Dave Ricks Nov 11, 2025 ▶ 24:21 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Nov 11, 2025 positive
Assertion Supported
Ricks: ICER found tirzepatide and semaglutide cost-effective at current pricing
“They just analyzed our medicines, trisepatide and semaglutide, and they said, actually, they're both cost effective at current pricing. In fact, Zepbound or Trisepatide was, the threshold they have is to save a 100,000 dollars per person per year in downstream…”
Dave Ricks Nov 11, 2025 ▶ 26:03 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Made with StarZero

Turn any episode into a week of clips.

This entire site, about 28 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.